Related Experiment Video
Updated: Aug 23, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
Inhibition of the proteasome reduces transfer-induced diabetes in nonobese diabetic mice
1Microbiology and Tumor Biology Center, Karolinska Institutet, S-171 77 Stockholm, Sweden.
Abstract:
Inhibition of the 26S proteasome reduces the severity of several immune-mediated diseases. Here, we report that the proteasome also regulates transfer-induced diabetes in nonobese mice. Treatment of recipient mice with the proteasome inhibitor N(alpha)-benzyloxycarbonyl-l-leucyl-l-leucyl-l-leucinal (MG132) resulted in a 76% reduction in transfer-induced diabetes. The closely related inhibitor carbobenzoxy-l-leucyl-l-leucinal that inhibits calpains but not the proteasome had no protective effect, suggesting that MG132 acted via inhibition of the proteasome. MG132 decreased proliferation of transferred T cells in the pancreatic lymph nodes in vivo and prevented their expansion in a dose-dependent manner in vitro, consistent with a direct effect by MG132 on the T cells. MG132 did not prevent migration of transferred T cells into the islets but reduced the number of mice with severe infiltration. We suggest that MG132 prevents transfer-induced diabetes by directly targeting the autoreactive T cells and lowering their diabetogenic potential.
Insights
Proteasome inhibition with MG132 significantly reduced transfer-induced diabetes in mice by targeting T cell proliferation. This suggests the proteasome plays a key role in the development of this autoimmune disease.
Area of Science:
- Immunology
- Endocrinology
- Molecular Biology
Background:
- The 26S proteasome is implicated in various immune-mediated diseases.
- Its role in transfer-induced diabetes, an autoimmune condition, is not well understood.
Purpose of the Study:
- To investigate the proteasome's role in regulating transfer-induced diabetes.
- To evaluate the therapeutic potential of proteasome inhibitors in this condition.
Main Methods:
- Treatment of nonobese mice with the proteasome inhibitor MG132.
- Assessment of diabetes incidence and severity.
- In vitro and in vivo analysis of T cell proliferation and migration.
Main Results:
- MG132 treatment reduced transfer-induced diabetes by 76%.
- MG132 inhibited T cell proliferation in pancreatic lymph nodes and in vitro.
- MG132 did not affect T cell migration but reduced severe islet infiltration.
Conclusions:
- The proteasome regulates transfer-induced diabetes.
- MG132 demonstrates therapeutic potential by targeting autoreactive T cells.
- Proteasome inhibition may be a viable strategy for treating autoimmune diabetes.
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type II Diabetes II: Pathophysiology
